HighTower Advisors’s AbbVie ABBV Stock Holding History

HighTower Advisors’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-100	Closed	-$180	–	3801
2024 Q3	$180	Buy	+100	New	+$18.7K	﹤0.01%	3708
2022 Q1	–	Sell	-15	Closed	-$67K	–	3394
2021 Q4	$67K	Sell	15 -785	-98%	-$92.7K	﹤0.01%	2991
2021 Q3	$1K	Buy	+800	New	+$91.4K	﹤0.01%	3108
2016 Q2	–	Sell	-40,100	Closed	-$66.2M	–	1760
2016 Q1	$66.2M	Buy	+40,100	New	+$2.24M	0.22%	22

Other funds holding ABBV

BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM

State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.21T AUM

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

JP Morgan Chase New York $1.84T AUM 33.86% 1-Year Est. Return

Morgan Stanley New York $1.96T AUM 27.49% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $704B AUM 26.74% 1-Year Est. Return

Franklin Resources San Mateo, California $474B AUM 32.39% 1-Year Est. Return

Capital World Investors Los Angeles, California $824B AUM 37.44% 1-Year Est. Return

HighTower Advisors's ABBV Position: Q3 2026 in Review

HighTower Advisors reduced its AbbVie (ABBV) stake by 0.45% in Q3 2026, selling an estimated $2.24M and leaving 1,958,587 shares worth $512M. The position accounts for 0.49% of the portfolio, ranked #33.

HighTower Advisors first reported a position in ABBV in Q2 2013 and has held it in 54 quarters since. 3,830 funds tracked by Wall St. Rank hold ABBV as of Q3 2026.

HighTower Advisors held 1,958,587 shares of AbbVie worth $512M as of Q3 2026.
HighTower Advisors sold 8,756 AbbVie shares in Q3 2026, an estimated $2.24M.
AbbVie made up 0.49% of HighTower Advisors's portfolio in Q3 2026, its #33 holding.
HighTower Advisors first reported a position in AbbVie in Q2 2013 and has held it in 54 quarters since.
3,830 funds tracked by Wall St. Rank held AbbVie as of Q3 2026.

Based on HighTower Advisors's 13F filing for Q3 2026, filed 10 Nov 2026.